Compare CNS & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNS | PLSE |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.6B |
| IPO Year | 2004 | 2015 |
| Metric | CNS | PLSE |
|---|---|---|
| Price | $78.18 | $48.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $71.50 | $22.00 |
| AVG Volume (30 Days) | 177.9K | ★ 476.8K |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.77 | N/A |
| Revenue | ★ $427,536,000.00 | N/A |
| Revenue This Year | $4.71 | $840.00 |
| Revenue Next Year | $4.37 | $287.54 |
| P/E Ratio | $45.15 | ★ N/A |
| Revenue Growth | ★ 4.07 | N/A |
| 52 Week Low | $58.39 | $12.56 |
| 52 Week High | $86.56 | $55.37 |
| Indicator | CNS | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 58.94 |
| Support Level | $76.15 | $24.27 |
| Resistance Level | $79.59 | N/A |
| Average True Range (ATR) | 2.51 | 2.96 |
| MACD | -0.62 | -0.28 |
| Stochastic Oscillator | 16.47 | 34.14 |
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests primarily in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for nearly two-thirds of its $102.5 billion in managed assets at the end of July 2026. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.